Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,122.11 30.59 0.99%
FTSE 100 6,567.21 25.60 0.39%
DAX 9,255.22 81.51 0.89%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

New Data From Epratuzumab to be Presented at EULAR 2013



New Data From Epratuzumab to be Presented at EULAR 2013

MORRIS PLAINS, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced that
Immunomedics and UCB (Euronext Brussels:UCB), a global biopharmaceutical
company with a focus on immunology treatment and research, will present new
data for their investigational studies of epratuzumab in systemic lupus
erythematosus (SLE) at the European League Against Rheumatism (EULAR) 2013
Congress to be held in Madrid, Spain, from June 12 – 15, 2013.

Epratuzumab is an investigational medicine in development for the treatment of
SLE. It is the first monoclonal antibody targeting CD22, a B-cell-specific
protein that regulates B-cell activity.^1,2 Epratuzumab is not licensed in
SLE.

Following is a guide to the investigational studies of epratuzumab for SLE
being presented as oral presentations or posters at EULAR.

  1. [OP0118]: Epratuzumab Mediates BCR-Antigen Trogocytosis As Potential
  Mechanism Of Action In Systemic Lupus Erythematosus (SLE)
  Goldenberg, D. et al.

    * Date/Time: June 13, 2013; 1120; Room N118
    * Session Info: Oral, Scientific Session

  2. [THU0045]: Epratuzumab, An Antibody Targeting CD22 On B Cells, Induces
  Phosphoprotein Changes Following B-Cell Receptor Activation In Vitro
  Lumb, S. et al.

    * Date/Time: June 13, 2013; 1145-1330
    * Session Info: Poster Tour, Poster Area

  3. [THU0277]: Epratuzumab: Sustained Safety Profile And Effect On
  Corticosteroid Use On Long-Term Treatment In Patients With
  Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label
  Long-Term Extension Study (SL0008)
  Wallace, D. et al.

    * Date/Time: June 13, 2013; 1145-1330
    * Session Info: Poster Session, Poster Area

  4. [THU0272]: Epratuzumab Maintains Improvements In Disease Activity For
  Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus
  Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008)
  Gordon, C. et al.

    * Date/Time: June 13, 2013; 1145-1330
    * Session Info: Poster Session, Poster Area

  5. [THU0286]: Immunologic Response To Long-Term Epratuzumab Treatment In
  SL0008, An Open-Label Longterm Extension Study In Patients With
  Moderate-To-Severe Systemic Lupus Erythematosus
  Strand, V. et al.

    * Date/Time: June 13, 2013; 1145-1330
    * Session Info: Poster Session, Poster Area

  6. [THU0029]: Epratuzumab Influences BCR Signalling On TLR9 Pre-Activated B
  Cells By Targeting CD22
  Sieger, N. et al.

    * Date/Time: June 13, 2013; 1145-1330
    * Session Info: Poster Session, Poster Area

References

  1. Sanz I., Eun-Hyung Lee F. B cells as therapeutic targets in SLE.
  Rheumatology; Vol. 6. 2010; Pp 326-327.

  2. Walker J., Smith K. B cells as therapeutic targets in SLE. Immunology;
  Vol. 123. 2008; Pp 314-325.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused
on the development of monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases. We have developed
a number of advanced proprietary technologies that allow us to create
humanized antibodies that can be used either alone in unlabeled or "naked"
form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or
toxins, in each case to create highly targeted agents. Using these
technologies, we have built a pipeline of therapeutic product candidates that
utilize several different mechanisms of action. We also have a majority
ownership in IBC Pharmaceuticals, Inc., which is developing a novel
DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and
multifunctional antibodies, and a new method of delivering imaging and
therapeutic agents selectively to disease, especially different solid cancers
(colorectal, lung, pancreas, etc.), by proprietary, antibody-based,
pretargeting methods. We believe that our portfolio of intellectual property,
which includes approximately 223 active patents in the United States and more
than 400 foreign patents, protects our product candidates and technologies.
Our strength in intellectual property has resulted in the top-10 ranking in
the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and
Pharmaceuticals category. For additional information on us, please visit our
website at www.immunomedics.com. The information on our website does not,
however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials, out-licensing arrangements (including the timing and amount of
contingent payments), forecasts of future operating results, potential
collaborations, and capital raising activities, involve significant risks and
uncertainties and actual results could differ materially from those expressed
or implied herein. Factors that could cause such differences include, but are
not limited to, risks associated with any cash payment that the Company might
receive in connection with a sublicense involving a third party and UCB, which
is not within the Company's control, new product development (including
clinical trials outcome and regulatory requirements/actions), our dependence
on our licensing partners for the further development of epratuzumab and
veltuzumab for non-cancer indications, competitive risks to marketed products
and availability of required financing and other sources of funds on
acceptable terms, if at all, as well as the risks discussed in the Company's
filings with the Securities and Exchange Commission. The Company is not under
any obligation, and the Company expressly disclaims any obligation, to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
         ccheng@immunomedics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement